STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
An approval for an ultra-rare disease arrived alongside preclinical gene-therapy work and a review of CRISPR-based biosensors.
TL;DR
- STAT reported that the FDA approved a new gene therapy for Sanfilippo syndrome, described as an ultra-rare disease.
- A bioRxiv preprint reports that neonatal AAV-SIL1 gene therapy prevents Marinesco-Sjogren syndrome in mice.
- A PubMed review covers signal transduction and engineering strategies for CRISPR-Cas biosensors.
The FDA approved a new gene therapy for Sanfilippo syndrome, according to STAT, which frames the condition as ultra-rare. The collection carries the approval at headline level, without label details, trial data or pricing. [1]
Preclinical work in the same feed covers a related modality: a bioRxiv preprint reports that neonatal AAV-SIL1 gene therapy prevents Marinesco-Sjogren syndrome in mice, a mouse-model result that has not been evaluated in humans. [2]
On the platform side, a PubMed review examines signal transduction and engineering strategies for CRISPR-Cas biosensors, a diagnostic rather than therapeutic use of gene-editing tools. [3]
Why it matters
Approvals in ultra-rare disease validate gene therapy as a commercial pathway even for very small patient populations, while the preclinical and biosensor items show the platform widening into new diseases and into diagnostics.
Editor's note
This is a headline-level approval report; the collection contains no clinical data, so the story states the approval and the adjacent research without extrapolating outcomes.